| INTRODUCTION
Osteosarcoma (OSA) is an osseous neoplasm that affects the appendicular skeleton of dogs. It accounts for approximately 85% of all bone tumors. 1, 2 Historically, the standard of care treatment has involved amputation of the affected limb followed by adjuvant chemotherapy. [3] [4] [5] Recent advancements in surgery and radiation therapy (RT) have allowed for salvage of the affected limb with reasonable rates of local MST, median survival time; OSA, osteosarcoma; OST, overall survival time; PET/CT, positron emission tomography/computed tomography; PFI, progression-free interval; ROI, region of interest; RT, radiation therapy; SRT, stereotactic radiation therapy; SUV max , maximum standard uptake value.
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control and similar survival times to amputation. [6] [7] [8] [9] Definitive treatment (ie, amputation, surgical limb spare, or high-dose RT) of the primary appendicular OSA in combination with adjuvant chemotherapy provides a median survival time (MST) of approximately 10-12 months, with most dogs dying of metastatic disease. 6, [8] [9] [10] [11] [12] [13] [14] There are multiple prognostic factors that are associated with a reduction in anticipated survival times in dogs with OSA, including pulmonary metastatic lesions visible on radiographs, 15 osseous or lymph node metastasis, 16, 17 elevated serum alkaline phosphatase (ALP) activity, 18 elevated blood monocyte count, 19 and primary tumor location. [20] [21] [22] Any of these factors identified on initial staging tests can indicate a change in prognosis and therefore influence therapeutic decisions. For example, the MST of dogs with visible pulmonary metastatic disease is reported as only 59 days. 15 As prognostic factors that negatively affect outcome can play such an important role in decision making for both the clinician and the owner, accurate staging before undertaking definitive treatment is vital. 
| Statistical analysis
Continuous data were assessed for normality using skewness, kurtosis, and Shapiro-Wilk tests. If the data were normally distributed, the mean and SD were used for description. The median and range were used if the data were non-normally distributed. Frequencies and percentages were used to describe any categorical variables.
The progression-free interval (PFI) was calculated as the number of days from the date of imaging to the date of initial detection of metasta- Statistical significance was set at α = 0.05 and the statistical analysis was performed by using commercially available software (SAS software, version 9.4. Cary, North Carolina).
| RESULTS
Seventy-seven dogs were identified that met the initial inclusion criteria. Of these, 11 dogs were excluded as carboplatin chemotherapy was not given and 4 were excluded when metastatic disease was confirmed at the time of initial imaging, leaving a total of 62 dogs included in the statistical analysis. The baseline characteristics of dogs are presented in Tables 1 and 2 .
For all dogs, the median PFI and all-cause OST were 320 and 284 days (95% CI, 219-378 days and 233-420 days, respectively); the median disease-specific OST was 434 days (95% CI, 279-811 days).
Thirty-one and 15 dogs were censored from PFI and OST analysis, The univariate analysis results are presented in Table 1 . The anatomic location of the primary tumor (proximal humerus versus any other location) and the type of treatment were not associated with any of the outcomes (PFI, all-cause OST, or disease specific). There were no variables including SUV max significantly associated with PFI.
Serum ALP activity and blood monocyte count were both significantly associated with OST for all cause and OST cause by disease.
Multivariable results are presented in Tables 3 and 4 47 There is conflicting evidence regarding the relationship between MI and prognosis for
OSAs. There is no relationship to survival of dogs with mandibular OSA and MI. 48 In other cases, MI influences disease-free interval (DFI) but not survival time of dogs with OSA, which is contrary to the finding of this study in which increase MI was associated with disease-specific OST but not DFI or all-cause OST. 43 In humans with malignant gastrointestinal stromal tumors, MI is significantly related to SUV max . 49 Maximum standard uptake value was not significantly associated with PFI. Because of the retrospective nature of this study, the exact . Survival time for this dog after 3 fractions of stereotactic radiation therapy (SRT) was 900 days, at which point the dog was euthanized because of "old age" as per the owner Abbreviations: ALP, alkaline phosphatase; CI, confidence interval; OST, overall survival time; SRT, stereotactic radiation therapy; SUV max , maximum standard uptake value. Tumor location was not significantly associated with survival in this study in spite of some previous studies stating that proximal humeral lesions have a poorer prognosis. 22 Other studies, however, have indicated that location does not impact survival, making the finding in this study consistent with previously reported outcomes. 7 In addition, serum ALP levels before treatment was not a prognostic factor for survival as an independent variable in the multivariable analysis. Given the retro- 
